Tarsus Pharmaceuticals Inc (TARS)

$36.2

-0.42

(-1.15%)▲

Live

Performance

  • $35.84
    $36.82
    $36.20
    downward going graph

    0.99%

    Downside

    Day's Volatility :2.66%

    Upside

    1.68%

    downward going graph
  • $12.84
    $42.50
    $36.20
    downward going graph

    64.53%

    Downside

    52 Weeks Volatility :69.79%

    Upside

    14.82%

    downward going graph

Returns

PeriodTarsus Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
34.93%
3.6%
0.0%
6 Months
13.41%
10.2%
0.0%
1 Year
180.61%
19.6%
0.0%
3 Years
33.02%
16.8%
-23.0%

Highlights

Market Capitalization
1.4B
Book Value
$6.63
Earnings Per Share (EPS)
-4.56
Wall Street Target Price
58.5
Profit Margin
-180.0%
Operating Margin TTM
-81.6%
Return On Assets TTM
-34.55%
Return On Equity TTM
-75.04%
Revenue TTM
83.4M
Revenue Per Share TTM
2.43
Quarterly Revenue Growth YOY
1004.5999999999999%
Gross Profit TTM
-17.8M
EBITDA
-155.3M
Diluted Eps TTM
-4.56
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.78
EPS Estimate Next Year
-2.37
EPS Estimate Current Quarter
-0.92
EPS Estimate Next Quarter
-0.88

Analyst Recommendation

Buy
    86%Buy
    13%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Tarsus Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 61.6%

Current $36.20
Target $58.50

Technicals Summary

Sell

Neutral

Buy

Tarsus Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc
10.37%
13.41%
180.61%
33.02%
77.94%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc
NA
NA
NA
-3.78
-0.75
-0.35
NA
6.63
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc
Buy
$1.4B
77.94%
NA
-180.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Tarsus Pharmaceuticals Inc

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 11.8%

Institutional Holdings

  • RTW INVESTMENTS, LLC

    8.97%

  • BlackRock Inc

    8.59%

  • Paradigm Biocapital Advisors LP

    6.40%

  • TANG CAPITAL MANAGEMENT LLC

    5.93%

  • COWEN AND COMPANY, LLC

    5.78%

  • Vanguard Group Inc

    5.23%

Company Information

tarsus pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. its lead product candidate is tp-03, a novel therapeutic that is in phase iib/iii for the treatment of blepharitis caused by the infestation of demodex mites, as well as to treat meibomian gland disease. the company is also developing tp-04 for the treatment of rosacea; and tp-05 for lyme prophylaxis and community malaria reduction. tarsus pharmaceuticals, inc. was founded in 2016 and is headquartered in irvine, california.

Organization
Tarsus Pharmaceuticals Inc
Employees
244
CEO
Dr. Bobak R. Azamian M.D.
Industry
Health Technology

Discover More

FAQs